Conditions: Advanced or Recurrent Solid Tumors Breast Neoplasms Ovarian Cancer, Epithelial Ewing Sarcoma Small Cell Lung Carcinoma Prostate Cancer Pancreas Cancer
Keywords: BRCA1 Protein BRCA2 Protein
Enrollment: 113
Healthy volunteers: no

Brief summary:
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalation phase in which the maximum tolerated dose will be defined, and a dose expansion phase.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Talazoparib
Intervention descriptions: intervention 1: Oral capsule with multiple dosage forms given once daily

Protocol document: